Rescheduling a drug means officially moving it from one category of controlled substances to another, changing how strictly the government regulates it. In the United States, every controlled substance is placed into one of five schedules based on its potential for abuse, whether it has an accepted medical use, and how likely it is to cause dependence. When new scientific evidence shows that a drug doesn’t belong where it was originally placed, the federal government can move it to a different schedule through a formal legal process.
How the Five Schedules Work
The Controlled Substances Act, passed in 1970, created five tiers of drug regulation. Schedule I is the most restrictive. A drug lands there if the government determines it has a high potential for abuse, no currently accepted medical use in the U.S., and no established safety profile even under medical supervision. Heroin and LSD are Schedule I substances.
Schedule II drugs also carry a high abuse potential, but they have an accepted medical use. Abuse can lead to severe physical or psychological dependence. Cocaine (used in certain medical procedures), fentanyl, and methamphetamine all sit in Schedule II.
From there, the restrictions loosen progressively. Schedule III substances have a lower abuse potential than Schedule II, with moderate or low risk of physical dependence. Schedule IV drugs have an even lower abuse potential, and Schedule V is the least restrictive, covering substances with minimal risk compared to everything above them. Importantly, every drug in Schedules II through V must have an accepted medical use. That distinction between “no medical use” and “accepted medical use” is one of the biggest legal dividing lines in the entire system.
What Triggers Rescheduling
Rescheduling typically starts when scientific evidence accumulates showing that a drug’s abuse potential, medical value, or dependence risk doesn’t match its current classification. The process can be initiated by the DEA, the Department of Health and Human Services (HHS), or a petition from essentially anyone: a drug manufacturer, a medical association, a pharmacy group, or even an individual person.
Once the process begins, the government evaluates the substance against eight specific factors. These include the drug’s actual potential for abuse, what science currently knows about how it works in the body, its history and patterns of abuse, the scope and severity of that abuse, the risk it poses to public health, and how likely it is to create physical or psychological dependence. The evaluation also considers whether the substance is a chemical precursor to something already controlled.
Who Makes the Decision
Two federal agencies share the work, but their roles are distinct. HHS, working through the FDA, conducts the scientific and medical evaluation. Their findings on the science are binding on the DEA during the proposal stage and carry significant weight through the final decision. The DEA, which operates under the Department of Justice, is the agency that actually makes the scheduling decision and publishes the rule.
After receiving the HHS recommendation, the DEA publishes a proposed rule in the Federal Register if it agrees rescheduling is warranted. A public comment period follows, during which anyone can weigh in. Any interested party can also request a formal hearing. After reviewing comments and conducting any hearings, the DEA publishes a final rule that officially changes the drug’s schedule.
This is not a quick process. It involves formal rulemaking, meaning it follows strict administrative procedures and can take months or years from start to finish.
Why Rescheduling Matters for Patients
The schedule a drug sits in directly affects how easy or difficult it is to prescribe, fill, and refill. Schedule II medications cannot be refilled at all. Every time you need more, your prescriber must write an entirely new prescription. A prescriber can issue multiple prescriptions at once covering up to a 90-day supply, but each one must be written separately, and the prescriber must note the earliest date each can be filled.
If that same drug were rescheduled to Schedule III, the prescription rules change dramatically. Schedule III and IV medications can be refilled up to five times within a six-month period. That means fewer office visits, fewer calls to your doctor’s office, and less disruption to your treatment. For patients managing chronic conditions, this difference is significant.
How It Changes Penalties
Federal trafficking penalties drop substantially at each schedule level. For Schedule I and II substances, a first trafficking offense can carry up to 20 years in prison and fines up to $1 million for an individual. For Schedule III substances, the maximum first offense drops to 10 years and $500,000. Schedule IV penalties cap at 5 years and $250,000 for a first offense. Rescheduling a drug doesn’t make it legal, but it significantly reduces the criminal consequences associated with it.
Effects on Research
Schedule I classification creates the highest barriers for researchers. Scientists who want to study a Schedule I substance face more stringent DEA registration requirements, additional paperwork, and tighter security protocols than those working with substances in any other schedule. Moving a drug to Schedule III or lower loosens those requirements considerably, making it easier for universities and pharmaceutical companies to conduct clinical trials and explore potential medical applications.
How Pharmacies Handle Different Schedules
Pharmacies face different storage and record-keeping requirements depending on the schedule. Schedule II medications require ordering through a special DEA form, and all records related to Schedule II drugs must be kept completely separate from every other business record. Pharmacies must also perform exact physical counts of all Schedule II inventory.
For Schedule III through V substances, the rules relax. Pharmacies can order them through standard invoices, store their records alongside regular business files (as long as they’re easy to find), and generally estimate inventory counts rather than performing exact ones. Rescheduling a drug from II to III, for example, reduces the administrative burden on every pharmacy that stocks it.
Marijuana Rescheduling as a Case Study
The most prominent rescheduling effort right now involves marijuana, which has been classified as Schedule I since 1970. In 2023, HHS recommended moving it to Schedule III after the FDA and the National Institute on Drug Abuse concluded the evidence supported rescheduling. In May 2024, the Department of Justice published a proposed rule to make the change, which drew nearly 43,000 public comments. As of late 2025, the proposal is awaiting an administrative law hearing.
Marijuana’s case also illustrates a complication that affects certain substances: international treaty obligations. The U.S. is a party to the 1961 Single Convention on Narcotic Drugs, which lists cannabis. A federal appeals court has previously ruled that placement in either Schedule I or Schedule II is necessary to satisfy U.S. obligations under that treaty, and that moving cannabis to Schedule III, IV, or V would not meet those requirements. How the government reconciles the current rescheduling proposal with this treaty constraint remains an open legal question.
Rescheduling vs. Descheduling
Rescheduling moves a drug from one schedule to another. Descheduling removes it from the controlled substances list entirely, meaning it would no longer be subject to DEA oversight or the special prescribing, dispensing, and record-keeping rules that apply to controlled substances. The same formal rulemaking process applies to both actions. A descheduled substance could still be regulated by the FDA as a prescription or over-the-counter drug, but it would no longer carry the additional legal weight of being a controlled substance.